-
Posted by
Two Blokes Jun 23 -
Filed in
Stock
-
4 views
Novo Nordisk (NYSE:NVO) delivered promising data over the weekend for its next-generation weight-loss injection, CagriSema, showing it can achieve weight reductions on par with the most effective treatments currently available. Yet the subdued market reaction on Monday suggests growing investor unease about how the Danish drugmaker will hold its lead in a rapidly crowding space.
